Literature DB >> 170450

[Elimination and excretion of adenylate kinases following cell damage].

W Sachsenheimer, R S Goody, R H Schirmer.   

Abstract

Adenylate kinases, small organ-specific isoenzymes which appear after tissue damage in the blood plasma are partly eliminated via the kidney. After intravenous administration of 3000 enzyme units of 14C-labelled adenylate kinase to rats, about 50% of the enzyme and of the radioactivity are found in the urine within 7 minutes. The elimination of adenylate kinase from the serum occurs in two phases, a faster (half-life 16 minutes) and a slower (half-life 160 minutes). After intravenous adminstration of adenylate kinase to humans, a part of the activity was recovered in the urine within minutes. The potential use of assaying adenylate kinase levels for early diagnosis of myocardial infarction is discussed. Using various skeletal muscle diseases as examples, the possible use of the very rapid elimination of adenylate kinase from the serum in monitoring the course of the acute illnesses is described. The competitive inhibitor diadenosine pentaphosphate (AP5A) has a much higher affinity for the adenylate kinases from erythrocytes, heart or skeletal muscle than for the isoenzymes from liver or kidney. Therefore, AP5A can be used for the differential determination of adenylate kinase isoenzymes in the blood plasma or the urine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170450     DOI: 10.1007/bf01469681

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

1.  [ON THE DETERMINATION OF MYOKINASE (ADENYLATE KINASE) ACTIVITY IN THE SERUM].

Authors:  F H SCHMIDT
Journal:  Klin Wochenschr       Date:  1964-05-15

2.  [Differences of enzyme activities in serum and plasma and their significance for the clinical enzyme diagnosis].

Authors:  H G SOLBACH; A ENGLHARDT; R MERTEN
Journal:  Klin Wochenschr       Date:  1962-11-15

3.  [Enzyme activity determinations in healthy human musculature and in myopathies. II. Enzyme activity changes in muscle in progressive muscular dystrophy].

Authors:  H HEYCK; G LAUDAHN; C J LUDERS
Journal:  Klin Wochenschr       Date:  1963-05-15

4.  Adenylate kinase in human tissue. II. Serum adenylate kinase and myocardial infarction.

Authors:  L H Bernstein; J M Horenstein; H D Sybers; P J Russell
Journal:  J Mol Cell Cardiol       Date:  1973-02       Impact factor: 5.000

5.  Adenylate kinase of porcine heart.

Authors:  S Kubo; L H Noda
Journal:  Eur J Biochem       Date:  1974-10-02

6.  P 1 ,P 5 -Di(adenosine-5')pentaphosphate, a potent multisubstrate inhibitor of adenylate kinase.

Authors:  G E Lienhard; I I Secemski
Journal:  J Biol Chem       Date:  1973-02-10       Impact factor: 5.157

7.  [The role of cardiac lymph in the transport of enzymes into the blood stream after myocardial infarction (author's transl)].

Authors:  P G Spieckermann; H Nordbeck; D Knoll; F V Kohl; K Sakai; H J Bretschneider
Journal:  Dtsch Med Wochenschr       Date:  1974-05-24       Impact factor: 0.628

8.  Preparation and characterization of a crystalline human ATP:AMP phosphotransferase.

Authors:  E Thuma; R H Schirmer; I Schirmer
Journal:  Biochim Biophys Acta       Date:  1972-04-07

9.  [Studies on enzyme disappearance. I. Half-lifes of some cell enzymes in man].

Authors:  U Bär; S Ohlendorf
Journal:  Klin Wochenschr       Date:  1970-07-01

10.  [The enzymatic diagnosis of myocardial infarction. II. Determination of organ-specific enzymes: creatine phosphokinase and myokinase].

Authors:  F G Lehmann; K W Schneider; H Menge
Journal:  Enzymol Biol Clin (Basel)       Date:  1966
View more
  1 in total

1.  CSF cyclic AMP and CSF adenylate kinase in cerebral ischaemic infarction.

Authors:  T Büttner; C R Hornig; O Busse; W Dorndorf
Journal:  J Neurol       Date:  1986-10       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.